Cancer Immunotherapy: Turning Your Immune System into a Weapon
- 1 day ago
- 3 min read
Introduction
Cancer has long been treated using conventional methods such as chemotherapy, radiation, and surgery. However, a revolutionary approach known as cancer immunotherapy is transforming the way we fight cancer. Instead of directly targeting tumors, immunotherapy empowers the body’s own immune system to recognize and destroy cancer cells more effectively.
What is Cancer Immunotherapy?
Cancer immunotherapy is a treatment strategy that enhances or modifies the immune system to identify and attack cancer cells. Normally, the immune system can detect abnormal cells, but cancer cells often develop mechanisms to evade immune detection. Immunotherapy works by “unmasking” these cells or boosting immune responses to eliminate them.
Types of Immunotherapy
Immune Checkpoint Inhibitors
These drugs block proteins such as PD-1, PD-L1, and CTLA-4 that prevent immune cells from attacking cancer cells. By inhibiting these checkpoints, T-cells can recognize and destroy tumors more effectively.
CAR-T Cell Therapy
This advanced approach involves modifying a patient’s T-cells in the laboratory to better recognize cancer cells before reintroducing them into the body.
Monoclonal Antibodies
These are lab-made molecules that bind to specific targets on cancer cells, marking them for destruction by the immune system.
How It Works
Cancer immunotherapy works by enhancing immune recognition and response:
Cancer cells produce signals that hide them from the immune system
Immunotherapy blocks these signals or strengthens immune cells
T-cells recognize and attack cancer cells
The immune system continues to monitor and destroy abnormal cells
Immunotherapy Workflow
Cancer Cells Evade Immune System
↓
Checkpoint Inhibitors / CAR-T Activation
↓
T-Cells Recognize Cancer Cells
↓
Immune Attack on Tumor
↓
Tumor Reduction & Immune Memory
Why It Matters: Real Statistics
According to the World Health Organization, cancer is responsible for nearly 10 million deaths annually worldwide (WHO, 2023). Immune checkpoint inhibitors have significantly improved survival rates in cancers such as melanoma and lung cancer, with some patients experiencing long-term remission (Vaddepally et al., 2020). The global cancer immunotherapy market is projected to exceed USD 150 billion by 2030, reflecting rapid adoption and innovation (Statista, 2024).
Advantages Over Traditional Treatments
Features | Immunotherapy | Chemotherapy |
Target specificity | High | Low |
Side effects | Often fewer | More severe |
Long-term protection | Yes (immune memory) | No |
Personalization | Increasing | Limited |
Immunotherapy offers a more targeted approach, reducing damage to healthy cells and improving patient outcomes.
Challenges and Limitations
Despite its success, immunotherapy is not effective for all patients. Some key challenges include:
● Variable response rates among individuals
● Immune-related side effects
● High treatment costs
● Limited effectiveness in certain cancer types
Ongoing research is focused on improving response rates and combining immunotherapy with other treatments for better outcomes.
Conclusion
Cancer immunotherapy represents a major breakthrough in modern medicine. By harnessing the body’s own immune system, it offers a more precise and potentially long-lasting approach to cancer treatment. As research continues to advance, immunotherapy is expected to play an increasingly central role in the fight against cancer, bringing us closer to more effective and personalized therapies.
References
Vaddepally, R.K. et al., 2020. Review of indications of FDA-approved immune checkpoint inhibitors. Journal of Hematology & Oncology, 13(1), pp.1–20.
World Health Organization (WHO), 2023. Cancer fact sheet. Geneva: WHO.
Statista Research Department, 2024. Cancer immunotherapy market size worldwide. Statista.
Tang, J. et al., 2021. The role of immune checkpoint inhibitors in cancer therapy. Signal Transduction and Targeted Therapy, 6(1), pp.1–15.
June, C.H. and Sadelain, M., 2020. Chimeric antigen receptor therapy. New England Journal of Medicine, 379(1), pp.64–73.
This article was prepared by Alisha Chantru (Brunel University).